StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Stock Down 13.8 %
CYCC stock opened at $0.77 on Friday. The business has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.65. The stock has a market cap of $1.12 million, a price-to-earnings ratio of -0.03 and a beta of 0.51. Cyclacel Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $11.34.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 21,963.75%. During the same quarter last year, the company earned ($6.60) earnings per share. As a group, sell-side analysts anticipate that Cyclacel Pharmaceuticals will post -2.29 EPS for the current year.
Institutional Trading of Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.
Read More
- Five stocks we like better than Cyclacel Pharmaceuticals
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- 3 Momentum Trades for October With Ample Upside Ahead
- Overbought Stocks Explained: Should You Trade Them?
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- What is a Special Dividend?
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.